Valeant Pharma (VRX) Reports Unsurprising Results Ahead of Dec. Meeting - FBR Capital
Tweet Send to a Friend
FBR Capital affirms Valeant Pharma (NYSE: VRX) at Outperform with a price target of $148 following Q3 results reported today.Analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
